SS Innovations International, Inc. (SSII) - 10-K Summary
Business Context and Reporting Period
Company: SS Innovations International, Inc. (SSII)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: SSII is a commercial-stage surgical robotics company headquartered in Gurugram, India, with a U.S. parent company. It designs, manufactures, and markets the SSi Mantra Surgical Robotic System, an affordable alternative to existing systems, targeting underserved markets globally. The company also offers instruments (SSi Mudra), accessories, and services including telesurgery and tele-proctoring.
Key Milestone: As of December 31, 2025, SSII had installed 168 systems (154 in India, 14 overseas) and performed over 7,885 surgical procedures. The company uplisted to the Nasdaq Stock Market in April 2025.
Key Financial Metrics
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Total Revenue | $42,484,747 | $20,649,528 |
| Gross Profit | $19,544,255 | $8,452,366 |
| Gross Margin | 46.0% | 40.9% |
| Net Loss | $(12,127,387) | $(19,151,197) |
| Operating Cash Flow | $(18,542,987) | $(9,503,030) |
| Cash & Restricted Cash | $9,603,020 | $6,623,535 |
| Total Assets | $74,226,217 | $42,385,213 |
| Total Liabilities | $36,007,966 | $28,928,110 |
| Stockholders' Equity | $38,218,251 | $13,457,103 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 106% year-over-year, driven by a significant rise in system sales ($38.4M vs. $19.5M) and instrument sales ($3.2M vs. $0.9M).
- Profitability: Net loss narrowed by 37% to $12.1M, primarily due to a $11.1M increase in gross profit and a $6.2M decrease in stock-based compensation expense.
- Expense Trends: Selling, General, and Administrative (SG&A) expenses increased 46% to $14.8M due to expanded commercial operations. R&D expenses rose 48% to $3.7M to support product development.
- Working Capital: Working capital surplus improved significantly to $22.6M from $6.1M in 2024, supported by a private placement and convertible note conversions.
- Stock-Based Compensation: Decreased substantially from $14.3M in 2024 to $8.1M in 2025, as large grants vested immediately in the prior year.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Outlook: SSII submitted a 510(k) premarket notification to the FDA in December 2025 and technical files to an EU Notified Body for CE certification. Management anticipates approvals in 2026 but notes no assurance of timing or success.
- Capital Raise: On March 6, 2026 (subsequent event), the company completed a private placement raising gross proceeds of $18.6M to fund working capital and global expansion.
- Going Concern: The auditor has issued a "Substantial Doubt" opinion regarding the company's ability to continue as a going concern due to recurring losses and negative operating cash flows, though the recent capital raise mitigates this risk.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including lack of written documentation and insufficient segregation of duties. Remediation efforts are underway.
- Legal Proceedings: The company faces a judgment of approximately $296,000 plus interest from a 2020 dispute with Quinn Emmanuel regarding legal fees, though the CEO has agreed to indemnify the company. There is also pending litigation regarding share ownership in a Bahamian subsidiary.
Investor Verification Checklist
- Regulatory Approval Status: Verify the timeline and probability of FDA 510(k) clearance and EU CE marking, as these are critical for U.S. and European market entry.
- Cash Burn Rate: Assess the runway provided by the $18.6M private placement against the $18.5M operating cash burn in 2025 to determine future funding needs.
- Revenue Recognition: Review the allocation of transaction prices in bundled contracts (systems, instruments, warranties) as this was identified as a critical audit matter.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting controls to ensure future financial statement reliability.
- Legal Indemnification: Confirm the enforceability of the indemnification agreement with the CEO regarding the Quinn Emmanuel legal judgment.